Understanding the Link Between COVID-19 Vaccines and Myocarditis: Key Insights to Clear the Confusion

Understanding Myocarditis Risks from COVID-19 and Vaccination

Introduction

This week, Melody clarifies the risks associated with myocarditis from COVID-19 compared to myocarditis resulting from the COVID-19 vaccine.

Reader Inquiry

A recent U.S. government report on COVID-19 vaccine safety has reignited discussions regarding the connection between myocarditis and mRNA vaccines. One of our readers expressed confusion about whether the vaccine increases the likelihood of myocarditis or its severity.

Dear Melody

Dear Melody,

I recently read an article from Medical News Bulletin discussing COVID-19 vaccine side effects. I understood that the vaccine makes myocarditis more likely, but I also saw numerous headlines claiming that vaccine-induced myocarditis is less severe. Which statement is accurate? What is the distinction?

Regards,
Skeptic Reader

Melody’s Response

Dear Skeptic Reader,

While there is a rare association between mRNA COVID-19 vaccination and myocarditis, the data indicates that you are approximately 50 times more likely to experience fatal outcomes from myocarditis caused by COVID-19 than from myocarditis linked to the vaccine.

In general, an individual with myocarditis has a 1% risk of mortality. If myocarditis is triggered by COVID-19, that risk escalates to between 10% and 20%. Conversely, myocarditis linked to mRNA vaccination carries a significantly lower risk of less than 0.5%.

Additionally, the mRNA vaccines do not substantially increase the risk of myocarditis. Global statistics reveal a minimal rise in myocarditis cases post-vaccination—about 1.2 additional cases per million vaccinations.

A report from the U.S. National Academy of Sciences highlights that only mRNA vaccines were associated with myocarditis. For those concerned about myocarditis, alternative vaccine technologies, such as adenovirus-based vaccines, are widely available.

It’s essential to clarify that a “higher risk” of myocarditis after vaccination suggests an increased likelihood of developing it, not that the myocarditis will be more severe or difficult to treat. In fact, the majority of vaccine-associated myocarditis cases have been mild, resolving quickly with appropriate care.

Clarifying the Confusion

The Medical News Bulletin article referenced by our reader summarized findings from the U.S. National Academy of Sciences regarding COVID-19 vaccines’ safety and effectiveness. The report concluded that the benefits of vaccination outweigh the risks, noting that while some adverse events occurred, they were infrequent and less severe than the consequences of COVID-19.

The focus of the report was on the incidence of symptoms rather than the severity of side effects, meaning it did not assess whether a reported side effect was dangerous—only that it had been documented.

Research Insights on Myocarditis

Meta-analyses, such as a 2022 study from the University of Oxford, demonstrate a significant difference in the mortality risks associated with myocarditis due to COVID-19 infection compared to vaccination. Myocarditis typically presents a 2% mortality rate, which increases to around 13% when caused by COVID-19. In contrast, the mortality rate for myocarditis induced by vaccination is about 0.44%. This discrepancy may be attributed to the demographics predominantly affected by vaccine-related myocarditis, particularly adolescent males, who generally face a lower risk of severe complications.

Understanding Myocarditis

Myocarditis occurs when heart muscle cells respond to perceived threats, releasing enzymes to combat infection and heal injuries. This response can lead to inflammation, complicating blood circulation and heart rhythm. Various factors, including viral and bacterial infections, autoimmune diseases, and certain medications, can trigger myocarditis. Severity often depends on the cause, the patient’s age, overall health, and the promptness of treatment.

Myocarditis resulting from COVID-19 infection tends to be more severe, with increased risks of complications and mortality.

Conclusion

In conclusion, while vaccination carries a slight increase in myocarditis risk, the severity and mortality associated with vaccine-related myocarditis are significantly lower compared to myocarditis caused by COVID-19. This data reinforces the critical role of vaccination in reducing the severe consequences of COVID-19.

According to the CDC, myocarditis following COVID-19 vaccination remains rare. Various studies and global safety monitoring systems have reported instances of vaccine-induced myocarditis, but this does not imply that all vaccinated individuals will experience these conditions. Instead, it suggests that mRNA vaccines can occasionally trigger myocarditis, influenced by additional factors.

Sincerely,
Editor

References

1. VAERS Home. Available at: https://vaers.hhs.gov/about.html (Accessed: 20 September 2024).
2. Ling RR, et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022;10(7):679-688.
3. Bemtgen, X. et al. Myocarditis mortality with and without COVID-19: Insights from a national registry. Clinical Research in Cardiology, 113(2), pp. 216–222.
4. Government of Canada, Canada.ca. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/type-viral-vector.html (Accessed: 23 September 2024).
5. Myocarditis and pericarditis after mRNA COVID-19 vaccination. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html (Accessed: 07 September 2024).
6. Clinical considerations: Myocarditis after COVID-19 vaccines. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html (Accessed: 20 September 2024).
7. Oster ME, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327(4):331-340.
8. Bürgi JJ, et al. Mild COVID-19 induces early, quantifiable, persistent troponin I elevations in elder men. Front Cardiovasc Med. 2022;9:1053790.
9. Paruchuri SSH, et al. Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature. Cureus. 2023;15(7):e42444.
10. Fairweather, D. et al. COVID-19, myocarditis and pericarditis. Circulation Research, 132(10), pp. 1302–1319.
11. Association between COVID-19 and myocarditis using hospital-based administrative data – United States, March 2020–January 2021. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e5.htm (Accessed: 20 September 2024).
12. Patone, M. et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-COV-2 infection by age and sex. Circulation, 146(10), pp. 743–754.
13. Rottmann, F.A. et al. Myocarditis incidence and hospital mortality from 2007 to 2022: Insights from a nationwide registry. Clinical Research in Cardiology [Preprint].